All In Biotech

Drug Trial Radar · NCT07449689

Comparing Acotiamide and Itopride for the Management of Indigestion

A Double-Blind Superiority Randomized Controlled Trial Comparing Acotiamide vs Itopride for Functional Dyspepsia Management

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 368 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

368

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Dec 2026

Study completion May 2027

Sponsor

Lead sponsor
Aga Khan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Searle Company Limited Pakistan
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blinded trial that will compare the effectiveness of two medications, acotiamide and itopride, in treating Functional Dyspepsia. Functional Dyspepsia causes uncomfortable symptoms arising from the gastro-duodenal region, such as fullness after meals, early satiation, stomach pain, and burning. The primary aim of this trial is to determine whether acotiamide is superior to itopride-specifically by a margin of 15%-at improving these meal-related digestive symptoms. Participants will be involved in the study for a total of 5 weeks. The study begins with a 7-day baseline period where participants will track their symptoms daily. Following the baseline period, participants will be randomly assigned to receive either 100mg of acotiamide three times a day or 50mg of itopride three times a day. The treatment phase will last for 4 weeks, during which participants will take the medication before meals on an empty stomach. Participants will continue to track their symptoms daily and will complete questionnaires about their overall treatment effect and quality of life at follow-up visits.

Conditions

  • Functioanl Dyspepsia
  • Post Prandial Distress Syndrome

Interventions

  • AcotiamideDrug

    100mg thrice daily, before meals on an empty stomach for 4 weeks.

  • itoprideDrug

    50mg thrice daily, before meals on an empty stomach for 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. : Overall Treatment Effect (OTE)Time frame: Week 1 and Week 4.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.